A Prospective Non-therapeutic Study in Patients Diagnosed With Niemann-Pick Disease Type C in Order to Characterise the Individual Patient Disease Profile and Historic Signo-symptomatology Progression Pattern
Latest Information Update: 24 Sep 2024
Price :
$35 *
At a glance
- Drugs Miglustat (Primary)
- Indications Niemann-Pick disease type C
- Focus Pharmacodynamics; Therapeutic Use
- Sponsors Orphazyme
- 24 Sep 2024 New trial record